Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N6I4
UPID:
LYSET_HUMAN
Alternative names:
GNPTAB cleavage and activity factor; Transmembrane protein 251
Alternative UPACC:
Q8N6I4; J3KQ65; Q9Y4S5
Background:
The Lysosomal enzyme trafficking factor, also known as GNPTAB cleavage and activity factor or Transmembrane protein 251, plays a pivotal role in mannose-6-phosphate-dependent trafficking of lysosomal enzymes. It acts as a bridge for the proteolytic activation of GNPTAB, crucial for Golgi-to-lysosome transport of lysosomal enzymes, and is indispensable for the maturation and delivery of lysosomal hydrolases.
Therapeutic significance:
Linked to Dysostosis multiplex, Ain-Naz type, a severe skeletal disease, understanding the role of Lysosomal enzyme trafficking factor could open doors to potential therapeutic strategies.